BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 29079518)

  • 1. Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection.
    Klumpp K; Shimada T; Allweiss L; Volz T; Lütgehetmann M; Hartman G; Flores OA; Lam AM; Dandri M
    Gastroenterology; 2018 Feb; 154(3):652-662.e8. PubMed ID: 29079518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus.
    Tsuge M; Uchida T; Hiraga N; Kan H; Makokha GN; Abe-Chayama H; Miki D; Imamura M; Ochi H; Hayes CN; Shimozono R; Iwamura T; Narumi H; Suzuki T; Kainoh M; Taniguchi T; Chayama K
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice.
    Uchida T; Imamura M; Hayes CN; Hiraga N; Kan H; Tsuge M; Abe-Chayama H; Zhang Y; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral Load Affects the Immune Response to HBV in Mice With Humanized Immune System and Liver.
    Dusséaux M; Masse-Ranson G; Darche S; Ahodantin J; Li Y; Fiquet O; Beaumont E; Moreau P; Rivière L; Neuveut C; Soussan P; Roingeard P; Kremsdorf D; Di Santo JP; Strick-Marchand H
    Gastroenterology; 2017 Dec; 153(6):1647-1661.e9. PubMed ID: 28851562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding Hepatitis B Virus Dynamics and the Antiviral Effect of Interferon Alpha Treatment in Humanized Chimeric Mice.
    Reinharz V; Ishida Y; Tsuge M; Durso-Cain K; Chung TL; Tateno C; Perelson AS; Uprichard SL; Chayama K; Dahari H
    J Virol; 2021 Jun; 95(14):e0049220. PubMed ID: 33910953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections.
    Kosaka K; Hiraga N; Imamura M; Yoshimi S; Murakami E; Nakahara T; Honda Y; Ono A; Kawaoka T; Tsuge M; Abe H; Hayes CN; Miki D; Aikata H; Ochi H; Ishida Y; Tateno C; Yoshizato K; Sasaki T; Chayama K
    Biochem Biophys Res Commun; 2013 Nov; 441(1):230-5. PubMed ID: 24140055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection.
    Yuen MF; Gane EJ; Kim DJ; Weilert F; Yuen Chan HL; Lalezari J; Hwang SG; Nguyen T; Flores O; Hartman G; Liaw S; Lenz O; Kakuda TN; Talloen W; Schwabe C; Klumpp K; Brown N
    Gastroenterology; 2019 Apr; 156(5):1392-1403.e7. PubMed ID: 30625297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B.
    Boglione L; Cariti G; Di Perri G; D'Avolio A
    J Med Virol; 2016 Nov; 88(11):1953-9. PubMed ID: 27017932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High persistence rate of hepatitis B virus in a hydrodynamic injection-based transfection model in C3H/HeN mice.
    Peng XH; Ren XN; Chen LX; Shi BS; Xu CH; Fang Z; Liu X; Chen JL; Zhang XN; Hu YW; Zhou XH
    World J Gastroenterol; 2015 Mar; 21(12):3527-36. PubMed ID: 25834317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy.
    Colombatto P; Civitano L; Bizzarri R; Oliveri F; Choudhury S; Gieschke R; Bonino F; Brunetto MR;
    Antivir Ther; 2006; 11(2):197-212. PubMed ID: 16640101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.
    Cai Q; Chen F; Shao X; Zhang X; Zhao Z; Gao Z
    Antivir Ther; 2015; 20(2):217-24. PubMed ID: 25138110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication.
    Lutgehetmann M; Volzt T; Quaas A; Zankel M; Fischer C; Dandri M; Petersen J
    Antivir Ther; 2008; 13(1):57-66. PubMed ID: 18389899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B virus limits response of human hepatocytes to interferon-α in chimeric mice.
    Lütgehetmann M; Bornscheuer T; Volz T; Allweiss L; Bockmann JH; Pollok JM; Lohse AW; Petersen J; Dandri M
    Gastroenterology; 2011 Jun; 140(7):2074-83, 2083.e1-2. PubMed ID: 21376046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.
    Buster EH; Hansen BE; Lau GK; Piratvisuth T; Zeuzem S; Steyerberg EW; Janssen HL
    Gastroenterology; 2009 Dec; 137(6):2002-9. PubMed ID: 19737568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
    PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes.
    Boglione L; D'Avolio A; Cariti G; Milia MG; Simiele M; De Nicolò A; Ghisetti V; Di Perri G
    J Viral Hepat; 2013 Apr; 20(4):e11-9. PubMed ID: 23490378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Characterization of NVR 3-778, a First-in-Class Capsid Assembly Modulator against Hepatitis B Virus.
    Lam AM; Espiritu C; Vogel R; Ren S; Lau V; Kelly M; Kuduk SD; Hartman GD; Flores OA; Klumpp K
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
    Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
    J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B virus sensitivity to interferon-α in hepatocytes is more associated with cellular interferon response than with viral genotype.
    Shen F; Li Y; Wang Y; Sozzi V; Revill PA; Liu J; Gao L; Yang G; Lu M; Sutter K; Dittmer U; Chen J; Yuan Z
    Hepatology; 2018 Apr; 67(4):1237-1252. PubMed ID: 29059468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of peginterferon alpha-2a vs. interferon alpha-2a on intrahepatic covalently closed circular DNA in HBeAg-positive chronic hepatitis B patients.
    Liu S; Zheng H; Huang Y; Li B; Dong Z
    Clin Res Hepatol Gastroenterol; 2016 Jun; 40(3):304-308. PubMed ID: 26382279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.